Products Categories
CAS No.: | 299-39-8 |
---|---|
Name: | SPARTEINE SULFATE |
Article Data: | 1 |
Molecular Structure: | |
Formula: | C15H26N2•H2O4S |
Molecular Weight: | 430.544 |
Synonyms: | siarczansparteiny;spal;spareng;sparm;sparteal;spartepur;spartin;spartocin |
Density: | g/cm3 |
Melting Point: | 135°C |
Boiling Point: | 340.9°Cat760mmHg |
Flash Point: | 148.3°C |
Risk Codes: | 23/25-33 |
Safety: | Poison by ingestion, subcutaneous, intravenous, and intraperitoneal routes. Human reproductive effects by intramuscular route: stillbirth; changes in uterus, cervix and vagina. When heated to decomposition it emits toxic fumes of NOx and SOx. |
PSA: | 89.46000 |
LogP: | 2.64890 |
Product Name: Sparteine sulfate
Synonyms: 7,14-Methano-2H,6H-dipyrido(1,2-a:1',2'-e)(1,5)diazocine, dodecahydro-, (7S-(7alpha,7aalpha,14alpha,14abeta))-, sulfate (1:1) (9CI) ; L-Spartein sulfat ; Spal ; Spareng ; Sparm
CAS NO: 299-39-8
Molecular Formula of Spartocin (CAS NO.299-39-8) : C15H28N2O4S
Molecular Weight of Spartocin (CAS NO.299-39-8) : 332.46
Molecular Structure of Spartocin (CAS NO.299-39-8) :
EINECS: 206-078-4
Flash Point: 148.3 °C
Enthalpy of Vaporization: 58.45 kJ/mol
Boiling Point: 340.9 °C at 760 mmHg
Vapour Pressure: 8.34E-05 mmHg at 25°C
Melting point: 135°C
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
frog | LDLo | parenteral | 375mg/kg (375mg/kg) | Journal of Pharmacology and Experimental Therapeutics. Vol. 27, Pg. 431, 1926. | |
guinea pig | LDLo | intraperitoneal | 42mg/kg (42mg/kg) | Journal of Agricultural Research Vol. 32, Pg. 51, 1926. | |
mouse | LD50 | intraperitoneal | 43mg/kg (43mg/kg) | Journal of Medicinal Chemistry. Vol. 20, Pg. 1668, 1977. | |
mouse | LD50 | intravenous | 15mg/kg (15mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: STIFFNESS BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) | Japanese Journal of Pharmacology. Vol. 16, Pg. 353, 1966. |
mouse | LD50 | oral | 350mg/kg (350mg/kg) | BEHAVIORAL: EXCITEMENT | Arzneimittel-Forschung. Drug Research. Vol. 30, Pg. 1497, 1980. |
mouse | LD50 | subcutaneous | 117mg/kg (117mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: STIFFNESS BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) | Japanese Journal of Pharmacology. Vol. 16, Pg. 353, 1966. |
rabbit | LDLo | subcutaneous | 80mg/kg (80mg/kg) | VASCULAR: REGIONAL OR GENERAL ARTERIOLAR OR VENOUS DILATION | Journal of Pharmacology and Experimental Therapeutics. Vol. 27, Pg. 431, 1926. |
rat | LD50 | intravenous | 30400ug/kg (30.4mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: STIFFNESS BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) | Japanese Journal of Pharmacology. Vol. 16, Pg. 353, 1966. |
Poison by ingestion, subcutaneous, intravenous, and intraperitoneal routes. Human reproductive effects by intramuscular route: stillbirth; changes in uterus, cervix and vagina. When heated to decomposition it emits toxic fumes of NOx and SOx.
Risk Statements 23/25-33
R23/25:Toxic by inhalation and if swallowed.
R33:Danger of cumulative effects.
Safety Statements 1-45
S1 :Keep locked up.
S45:In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
RIDADR 1544
HazardClass 6.1(b)
PackingGroup III